Lifeward Ltd. filings document regulatory disclosures for a Nasdaq-listed medical technology company whose ordinary shares trade under LFWD. The filing record includes Form 8-K material-event reports, annual-report references, shareholder vote results, and disclosures tied to its rehabilitation and recovery technology business.
Recent filings cover a completed acquisition, related ordinary-share and warrant consideration, a reverse share split, amendments to articles of association, authorized share-capital changes, and Nasdaq listing-compliance matters. The filings also document board and audit committee governance, officer employment and compensation arrangements, operating and financial results, material agreements, risk factors, and clinical or regulatory disclosures.
Lifeward Ltd. received a notification from The Nasdaq Stock Market that its closing bid price has been below the required minimum of $1.00 per share for the last 30 consecutive business days. The notice is a deficiency, not a delisting, and does not currently affect the listing or trading of the companys ordinary shares.
The company has 180 days to regain compliance, until February 2, 2026, by maintaining a closing bid price of at least $1.00 for 10 consecutive business days. Lifeward may be eligible for a second 180-day cure period if, as of that date, it has a market value of publicly held shares of at least $1 million, meets other initial listing standards except the bid price requirement, and provides written notice of its intent to cure.
Management states it will monitor the closing bid price and consider plans to regain compliance but expressly warns there is no assurance it will be able to do so within the cure period or any extension. The report includes customary forward-looking statements and refers readers to the companys SEC filings for additional risk factors.
Form 4 filing for Lifeward Ltd. (LFWD) discloses one routine equity award to non-executive director Randel Richner.
- Transaction: On 01-Aug-2025 the director received 35,920 restricted stock units (RSUs) of ordinary shares (par NIS 1.75) at $0 cost.
- Vesting schedule: RSUs vest in four equal quarterly instalments beginning three months after the grant date.
- Post-grant holdings: Richner now indirectly owns 57,487 shares through the company ESOP.
- No derivative securities, sales, or open-market purchases were reported.
The filing reflects standard board compensation intended to align director interests with shareholders. The modest share count suggests immaterial dilution at the company level and no immediate cash impact.
Form 4 filing for Lifeward Ltd. (LFWD) discloses the first reportable transaction by director Hadar Levy on 1 Aug 2025.
- Transaction: Acquisition of 35,920 ordinary shares via restricted stock units (RSUs) granted under the 2025 Incentive Compensation Plan. The award was booked at $0.00 cost, indicating a compensation grant rather than a market purchase.
- Vesting terms: RSUs vest in four equal quarterly tranches beginning three months after the grant date.
- Post-transaction ownership: Levy now holds 51,576 shares indirectly through the company ESOP.
- The reported share balances already reflect Lifeward’s 1-for-7 reverse share split effective 15 Mar 2024.
No derivative securities or sales were reported. The filing shows additional equity alignment for a board member but does not involve cash outlay or immediate market activity, so short-term dilution and trading-signal effects are minimal.
Form 4 snapshot for Lifeward Ltd. (LFWD): On 08/01/2025 director Joseph E. Turk Jr. received 71,839 restricted stock units (RSUs) under the 2025 Incentive Compensation Plan. The award carries no cash consideration (price $0.00) and will vest in four equal quarterly tranches beginning three months after the grant date.
The filing also shows a disposition of 18,516 ordinary shares and reports total indirect beneficial ownership of 86,457 ordinary shares held through the company ESOP following the transactions. No derivative securities were involved.
Because the RSUs are an equity-based incentive, cash flow is unaffected; any dilution impact is minimal relative to Lifeward’s outstanding share count (not disclosed in the filing). The transaction signals continued board-level alignment with shareholders but does not, by itself, alter the firm’s fundamentals or outlook.
Lifeward (Nasdaq: LFWD) filed an 8-K reporting entry into a Material Definitive Agreement for a best-efforts public offering that closed on 26 Jun 2025.
The company sold 4 million ordinary shares and 4 million five-year warrants at a combined $0.65, raising ~$2.0 million net after fees. H.C. Wainwright acted as placement agent, earning 8% in cash fees, expense reimbursements and 240,000 warrants exercisable at $0.8125.
The Purchase Agreement restricts additional share issuances for 30 days and bans variable-rate financings for one year, easing near-term dilution concerns. Proceeds will fund commercial expansion, working capital and general corporate purposes. The securities were registered on Form S-1 (File No. 333-288172) declared effective 25 Jun 2025.